Crenessity CAH denied due to quantity / dose limits by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for crenessity cah are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Applies Quantity Limits to Crenessity for CAH — and Why You Can Appeal

Blue Cross Blue Shield may apply quantity limits to Crenessity (tildacerfont) — approving coverage only for a specific number of units or a specific day supply per fill — based on its formulary management policy. When your prescriber orders a quantity that exceeds the plan's limit, the claim is denied for the excess amount. This commonly occurs when the prescribed quantity differs from the FDA-approved dosing schedule as interpreted by the plan, or when a prescriber has titrated the dose for clinical reasons.

Quantity-limit denials can be appealed successfully when the chart documents the clinical rationale for the ordered quantity, and when that rationale maps to the FDA-approved prescribing information.

## Federal Appeal Rights

• ACA §2719 external review: After exhausting internal appeals, you may request independent external review within approximately four months of the final denial notice — confirm the exact deadline on your denial letter. Expedited review is available for urgent situations.
• ERISA §503: Employer-plan members are entitled to a written explanation of the specific quantity limit applied and the plan provision authorizing it.

## Concrete Appeal Steps

1. Identify the exact limit applied. Request BCBS's current quantity-limit policy for Crenessity (the specific units per fill or day supply allowed). Compare it to the FDA-approved prescribing information in the current label. 2. Confirm the prescribed quantity against the FDA label. If the prescribed quantity falls within the FDA-approved dosing range, document this explicitly in your appeal — attach the relevant section of the label. 3. If the prescriber ordered above the standard quantity: Obtain a letter from the prescriber documenting the clinical reason for the quantity ordered, citing specific chart findings (not invented statistics) that support the clinical decision. 4. Gather clinical documentation: CAH diagnosis records, current prescriber order, clinical notes, and any prior prescription history. 5. File the internal appeal within the plan's stated deadline, with the FDA label, prescriber letter, and clinical records attached.

## Criteria-Mapping Structure

| BCBS Quantity-Limit Basis | Your Documentation | |---|---| | Quantity exceeds plan limit | Plan's stated limit (from policy); FDA label dosing range | | Ordered quantity outside FDA-approved range | FDA prescribing information confirming ordered quantity is within range, or prescriber letter if it differs | | Clinical necessity for ordered quantity | Prescriber letter citing chart-documented clinical reason |

Obtain both the FDA prescribing label (from Drugs@FDA) and BCBS's current quantity-limit schedule for Crenessity before filing, so your appeal directly compares the two documents.